BMJ Open Respiratory Research (Jul 2024)

Risk factors of acute exacerbation and disease progression in young patients with COPD

  • Deog Kyeom Kim,
  • Jung-Kyu Lee,
  • Eun Young Heo,
  • Hyun Woo Lee,
  • Chang Hoon Lee,
  • Hyo Jin Lee,
  • Juye Bae,
  • Kwang Yong Choi,
  • Tae Yun Park

DOI
https://doi.org/10.1136/bmjresp-2023-001740
Journal volume & issue
Vol. 11, no. 1

Abstract

Read online

Objective We aimed to elucidate the clinical factors associated with acute exacerbation and disease progression in young patients with chronic obstructive pulmonary disease (COPD).Methods This retrospective longitudinal observational study included patients with COPD aged between 20 and 50 years with post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC)<0.7. Eligible patients were followed up with ≥2 spirometry examinations at 1 year interval after COPD diagnosis. The primary outcome was moderate-to-severe acute exacerbation in young patients with COPD. Secondary outcomes were early initiation of regular inhalation therapy and accelerated annual post-bronchodilator FEV1 decline.Results A total of 342 patients were followed up during a median of 64 months. In multivariable analyses, risk factors for moderate-to-severe exacerbation were history of asthma (adjusted HR (aHR)=2.999, 95% CI=[2.074–4.335]), emphysema (aHR=1.951, 95% CI=[1.331–2.960]), blood eosinophil count >300/µL (aHR=1.469, 95% CI=[1.038–2.081]) and low FEV1 (%) (aHR=0.979, 95% CI=[0.970–0.987]). A history of asthma, sputum, blood eosinophil count >300/µL, low FEV1 (%) and low diffusing capacity of the lung for carbon monoxide (DLCO) (%) were identified as clinical factors associated with the early initiation of regular inhalation therapy. The risk factors associated with worsened FEV1 decline were increasing age, female sex, history of pulmonary tuberculosis, sputum, low FEV1 (%) and low DLCO (%).Conclusions In young COPD patients, specific high-risk features of acute exacerbation and disease progression need to be identified, including a history of previous respiratory diseases, current respiratory symptoms, blood eosinophil counts, and structural or functional pulmonary impairment.